TISIDB

Summary
Symbol	SPN
Name	sialophorin
Aliases	LSN; CD43; GPL115; leukosialin; sialophorin (gpL115, leukosialin, CD43); GALGP; galactoglycoprotein; leukocy ......
Chromosomal Location	16p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Membrane Single-pass type I membrane protein Cell projection, microvillus Cell projection, uropodium Note=Localizes to the uropodium and microvilli via its interaction with ERM proteins (EZR, RDX and MSN). ; SUBCELLULAR LOCATION: CD43 cytoplasmic tail: Nucleus Nucleus, PML body
Domain	-
Function	Predominant cell surface sialoprotein of leukocytes which regulates multiple T-cell functions, including T-cell activation, proliferation, differentiation, trafficking and migration. Positively regulates T-cell trafficking to lymph-nodes via its association with ERM proteins (EZR, RDX and MSN) (By similarity). Negatively regulates Th2 cell differentiation and predisposes the differentiation of T-cells towards a Th1 lineage commitment. Promotes the expression of IFN-gamma by T-cells during T-cell receptor (TCR) activation of naive cells and induces the expression of IFN-gamma by CD4(+) T-cells and to a lesser extent by CD8(+) T-cells (PubMed:18036228). Plays a role in preparing T-cells for cytokine sensing and differentiation into effector cells by inducing the expression of cytokine receptors IFNGR and IL4R, promoting IFNGR and IL4R signaling and by mediating the clustering of IFNGR with TCR (PubMed:24328034). Acts as a major E-selectin ligand responsible for Th17 cell rolling on activated vasculature and recruitment during inflammation. Mediates Th17 cells, but not Th1 cells, adhesion to E-selectin. Acts as a T-cell counter-receptor for SIGLEC1 (By similarity). ; FUNCTION: CD43 cytoplasmic tail: Protects cells from apoptotic signals, promoting cell survival.

> Gene Ontology [ TOP ]
Biological Process	GO:0001562 response to protozoan GO:0001806 type IV hypersensitivity GO:0001807 regulation of type IV hypersensitivity GO:0001808 negative regulation of type IV hypersensitivity GO:0001819 positive regulation of cytokine production GO:0002250 adaptive immune response GO:0002437 inflammatory response to antigenic stimulus GO:0002438 acute inflammatory response to antigenic stimulus GO:0002443 leukocyte mediated immunity GO:0002449 lymphocyte mediated immunity GO:0002456 T cell mediated immunity GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002521 leukocyte differentiation GO:0002524 hypersensitivity GO:0002526 acute inflammatory response GO:0002673 regulation of acute inflammatory response GO:0002674 negative regulation of acute inflammatory response GO:0002683 negative regulation of immune system process GO:0002694 regulation of leukocyte activation GO:0002695 negative regulation of leukocyte activation GO:0002696 positive regulation of leukocyte activation GO:0002697 regulation of immune effector process GO:0002698 negative regulation of immune effector process GO:0002703 regulation of leukocyte mediated immunity GO:0002704 negative regulation of leukocyte mediated immunity GO:0002706 regulation of lymphocyte mediated immunity GO:0002707 negative regulation of lymphocyte mediated immunity GO:0002709 regulation of T cell mediated immunity GO:0002710 negative regulation of T cell mediated immunity GO:0002819 regulation of adaptive immune response GO:0002820 negative regulation of adaptive immune response GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002823 negative regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002831 regulation of response to biotic stimulus GO:0002861 regulation of inflammatory response to antigenic stimulus GO:0002862 negative regulation of inflammatory response to antigenic stimulus GO:0002864 regulation of acute inflammatory response to antigenic stimulus GO:0002865 negative regulation of acute inflammatory response to antigenic stimulus GO:0002883 regulation of hypersensitivity GO:0002884 negative regulation of hypersensitivity GO:0006968 cellular defense response GO:0007159 leukocyte cell-cell adhesion GO:0007162 negative regulation of cell adhesion GO:0007163 establishment or maintenance of cell polarity GO:0009615 response to virus GO:0022407 regulation of cell-cell adhesion GO:0022408 negative regulation of cell-cell adhesion GO:0022409 positive regulation of cell-cell adhesion GO:0030098 lymphocyte differentiation GO:0030217 T cell differentiation GO:0031294 lymphocyte costimulation GO:0031295 T cell costimulation GO:0031348 negative regulation of defense response GO:0032102 negative regulation of response to external stimulus GO:0032640 tumor necrosis factor production GO:0032680 regulation of tumor necrosis factor production GO:0032760 positive regulation of tumor necrosis factor production GO:0032943 mononuclear cell proliferation GO:0032944 regulation of mononuclear cell proliferation GO:0032945 negative regulation of mononuclear cell proliferation GO:0032946 positive regulation of mononuclear cell proliferation GO:0033077 T cell differentiation in thymus GO:0042035 regulation of cytokine biosynthetic process GO:0042089 cytokine biosynthetic process GO:0042098 T cell proliferation GO:0042102 positive regulation of T cell proliferation GO:0042107 cytokine metabolic process GO:0042108 positive regulation of cytokine biosynthetic process GO:0042110 T cell activation GO:0042129 regulation of T cell proliferation GO:0042130 negative regulation of T cell proliferation GO:0042533 tumor necrosis factor biosynthetic process GO:0042534 regulation of tumor necrosis factor biosynthetic process GO:0042535 positive regulation of tumor necrosis factor biosynthetic process GO:0042742 defense response to bacterium GO:0043383 negative T cell selection GO:0043900 regulation of multi-organism process GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism GO:0045058 T cell selection GO:0045060 negative thymic T cell selection GO:0045061 thymic T cell selection GO:0045785 positive regulation of cell adhesion GO:0046651 lymphocyte proliferation GO:0050670 regulation of lymphocyte proliferation GO:0050671 positive regulation of lymphocyte proliferation GO:0050672 negative regulation of lymphocyte proliferation GO:0050688 regulation of defense response to virus GO:0050727 regulation of inflammatory response GO:0050728 negative regulation of inflammatory response GO:0050777 negative regulation of immune response GO:0050792 regulation of viral process GO:0050863 regulation of T cell activation GO:0050865 regulation of cell activation GO:0050866 negative regulation of cell activation GO:0050867 positive regulation of cell activation GO:0050868 negative regulation of T cell activation GO:0050870 positive regulation of T cell activation GO:0050900 leukocyte migration GO:0051249 regulation of lymphocyte activation GO:0051250 negative regulation of lymphocyte activation GO:0051251 positive regulation of lymphocyte activation GO:0051607 defense response to virus GO:0070486 leukocyte aggregation GO:0070489 T cell aggregation GO:0070661 leukocyte proliferation GO:0070663 regulation of leukocyte proliferation GO:0070664 negative regulation of leukocyte proliferation GO:0070665 positive regulation of leukocyte proliferation GO:0071593 lymphocyte aggregation GO:0071594 thymocyte aggregation GO:0071706 tumor necrosis factor superfamily cytokine production GO:0098542 defense response to other organism GO:1903037 regulation of leukocyte cell-cell adhesion GO:1903038 negative regulation of leukocyte cell-cell adhesion GO:1903039 positive regulation of leukocyte cell-cell adhesion GO:1903555 regulation of tumor necrosis factor superfamily cytokine production GO:1903557 positive regulation of tumor necrosis factor superfamily cytokine production
Molecular Function	-
Cellular Component	GO:0001931 uropod GO:0005578 proteinaceous extracellular matrix GO:0005604 basement membrane GO:0009897 external side of plasma membrane GO:0031254 cell trailing edge GO:0044420 extracellular matrix component GO:0098552 side of membrane

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04514 Cell adhesion molecules (CAMs)
Reactome	R-HSA-210991: Basigin interactions R-HSA-202733: Cell surface interactions at the vascular wall R-HSA-109582: Hemostasis

Summary
Symbol	SPN
Name	sialophorin
Aliases	LSN; CD43; GPL115; leukosialin; sialophorin (gpL115, leukosialin, CD43); GALGP; galactoglycoprotein; leukocy ......
Chromosomal Location	16p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between SPN and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between SPN and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
24356816	Acute Lymphoblastic Leukemia	Inhibit immunity; Immunotherapy target	Cancer-associated CD43 glycoforms as target of immunotherapy. CD43 is a sialoglycosylated membrane protein that is involved in cell proliferation and differentiation. The cancer association of UN1/CD43 epitope suggested the possibility to use the UN1 mAb for tumor diagnosis and therapy.

Summary
Symbol	SPN
Name	sialophorin
Aliases	LSN; CD43; GPL115; leukosialin; sialophorin (gpL115, leukosialin, CD43); GALGP; galactoglycoprotein; leukocy ......
Chromosomal Location	16p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of SPN in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	SPN
Name	sialophorin
Aliases	LSN; CD43; GPL115; leukosialin; sialophorin (gpL115, leukosialin, CD43); GALGP; galactoglycoprotein; leukocy ......
Chromosomal Location	16p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of SPN in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.062	0.879
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.449	0.607
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.427	0.495
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.467	0.239
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.39	0.803
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.566	0.777
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.355	0.512
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.568	0.617
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.088	0.945
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.633	0.122
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.243	0.459
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.196	0.353

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of SPN in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	5.9	-5.9	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	33.3	-33.3	0.231
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	1.4	2.3	0.469
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	1.7	2	0.532
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	0	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	3.7	-1.1	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	7.1	-7.1	0.467
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	SPN
Name	sialophorin
Aliases	LSN; CD43; GPL115; leukosialin; sialophorin (gpL115, leukosialin, CD43); GALGP; galactoglycoprotein; leukocy ......
Chromosomal Location	16p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SPN. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	SPN
Name	sialophorin
Aliases	LSN; CD43; GPL115; leukosialin; sialophorin (gpL115, leukosialin, CD43); GALGP; galactoglycoprotein; leukocy ......
Chromosomal Location	16p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SPN. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SPN. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	SPN
Name	sialophorin
Aliases	LSN; CD43; GPL115; leukosialin; sialophorin (gpL115, leukosialin, CD43); GALGP; galactoglycoprotein; leukocy ......
Chromosomal Location	16p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SPN. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	SPN
Name	sialophorin
Aliases	LSN; CD43; GPL115; leukosialin; sialophorin (gpL115, leukosialin, CD43); GALGP; galactoglycoprotein; leukocy ......
Chromosomal Location	16p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of SPN expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	SPN
Name	sialophorin
Aliases	LSN; CD43; GPL115; leukosialin; sialophorin (gpL115, leukosialin, CD43); GALGP; galactoglycoprotein; leukocy ......
Chromosomal Location	16p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between SPN and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	SPN
Name	sialophorin
Aliases	LSN; CD43; GPL115; leukosialin; sialophorin (gpL115, leukosialin, CD43); GALGP; galactoglycoprotein; leukocy ......
Chromosomal Location	16p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting SPN collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse SPN